This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
acute respiratory | 1330 |
influenza virus | 1090 |
respiratory syndrome | 1060 |
public health | 996 |
severe acute | 845 |
amino acid | 835 |
mg ml | 796 |
respiratory tract | 738 |
plos one | 731 |
virus infection | 720 |
gene expression | 681 |
one doi | 673 |
cord uid | 672 |
doc id | 672 |
immune response | 655 |
infectious diseases | 646 |
united states | 558 |
cell lines | 537 |
immune responses | 536 |
infected cells | 521 |
influenza viruses | 502 |
respiratory viruses | 499 |
amino acids | 473 |
novel coronavirus | 472 |
previously described | 465 |
present study | 457 |
previous studies | 456 |
syndrome coronavirus | 455 |
epithelial cells | 441 |
performed using | 426 |
mental health | 426 |
statistically significant | 412 |
risk factors | 412 |
type i | 404 |
avian influenza | 402 |
viral rna | 398 |
viral infection | 392 |
immunodeficiency virus | 389 |
pandemic influenza | 385 |
coronavirus disease | 384 |
infectious disease | 383 |
respiratory syncytial | 373 |
confirmed cases | 373 |
ns pro | 368 |
health care | 368 |
syncytial virus | 366 |
hong kong | 363 |
virus type | 359 |
room temperature | 352 |
cell line | 348 |
time pcr | 344 |
viral replication | 340 |
respiratory infections | 340 |
human immunodeficiency | 335 |
viral load | 332 |
significantly higher | 330 |
nucleic acid | 322 |
social media | 319 |
cell culture | 318 |
total number | 313 |
world health | 302 |
innate immune | 297 |
reverse transcription | 295 |
lower respiratory | 293 |
described previously | 291 |
least one | 290 |
viral infections | 281 |
prostate cancer | 279 |
health organization | 278 |
reproduction number | 275 |
significant differences | 275 |
cd cd | 272 |
systematic review | 270 |
codon usage | 265 |
time points | 261 |
control group | 260 |
expression levels | 256 |
respiratory infection | 248 |
social distancing | 244 |
intensive care | 244 |
seasonal influenza | 243 |
virus replication | 242 |
age groups | 242 |
respiratory disease | 241 |
immune system | 240 |
western blot | 239 |
ng ml | 238 |
middle east | 237 |
host cell | 237 |
significant difference | 234 |
clinical characteristics | 234 |
age group | 231 |
protein expression | 230 |
disease control | 229 |
ebola virus | 228 |
polymerase chain | 224 |
logistic regression | 224 |
chain reaction | 222 |
vero cells | 220 |
years old | 219 |
disease severity | 218 |
cell cycle | 215 |
may also | 215 |
sars coronavirus | 213 |
sample size | 212 |
tract infections | 211 |
negative control | 209 |
rna viruses | 209 |
human bocavirus | 207 |
neutralizing antibodies | 207 |
supporting information | 206 |
east respiratory | 205 |
well plates | 204 |
serum samples | 203 |
acquired pneumonia | 203 |
vaccinia virus | 199 |
closely related | 197 |
three times | 197 |
informed consent | 197 |
important role | 195 |
pcr assay | 195 |
cell surface | 195 |
total rna | 193 |
influenza infection | 193 |
mg kg | 192 |
flow cytometry | 192 |
mm tris | 190 |
dengue virus | 189 |
wild type | 188 |
porcine epidemic | 188 |
previously reported | 187 |
time point | 187 |
infected individuals | 186 |
infected patients | 185 |
nk cells | 185 |
mrna expression | 184 |
clinical signs | 184 |
standard deviation | 183 |
dendritic cells | 183 |
control measures | 182 |
membrane fusion | 182 |
respiratory illness | 182 |
ffi ffi | 181 |
pregnant women | 181 |
respiratory virus | 180 |
cell death | 180 |
ffl ffl | 180 |
results suggest | 179 |
binding site | 178 |
monoclonal antibodies | 178 |
neutralizing antibody | 178 |
influenza vaccine | 176 |
study period | 174 |
current study | 174 |
risk factor | 173 |
phylogenetic analysis | 172 |
virus infections | 172 |
taken together | 170 |
highly pathogenic | 170 |
epidemic diarrhea | 170 |
disease virus | 169 |
goat anti | 169 |
general population | 169 |
mechanical ventilation | 167 |
rna polymerase | 167 |
time series | 166 |
influenza pandemic | 166 |
large number | 165 |
hospitalized patients | 165 |
spike protein | 164 |
crystal structure | 164 |
antiviral activity | 163 |
viral proteins | 163 |
type ii | 163 |
peripheral blood | 163 |
reverse transcriptase | 163 |
poly i | 163 |
respiratory distress | 163 |
results showed | 162 |
cell responses | 162 |
applied biosystems | 161 |
cov infection | 160 |
statistical significance | 160 |
mhc class | 160 |
determine whether | 160 |
contact tracing | 159 |
diarrhea virus | 159 |
human metapneumovirus | 158 |
data collection | 156 |
class i | 156 |
previous study | 154 |
human coronavirus | 154 |
severe disease | 153 |
social support | 152 |
also found | 152 |
significantly increased | 152 |
antibody response | 151 |
analyzed using | 151 |
higher levels | 150 |
secondary structure | 150 |
west nile | 150 |
herpes simplex | 150 |
two groups | 149 |
like receptor | 149 |
mouse model | 149 |
time rt | 148 |
specific cd | 148 |
escherichia coli | 147 |
highly conserved | 147 |
active site | 147 |
care unit | 147 |
high levels | 146 |
infected mice | 145 |
growth factor | 145 |
monoclonal antibody | 144 |
cell types | 144 |
cohort study | 144 |
real time | 143 |
critically ill | 143 |
respiratory symptoms | 142 |
also observed | 142 |
pcr products | 142 |
significantly different | 142 |
bovine serum | 142 |
infectious bronchitis | 141 |
severe cases | 141 |
two different | 140 |
even though | 140 |
ethics committee | 140 |
mm nacl | 140 |
significantly lower | 140 |
structural proteins | 139 |
viral entry | 139 |
hospitalized children | 139 |
porcine reproductive | 139 |
high risk | 138 |
south africa | 138 |
influenza vaccination | 138 |
lung injury | 138 |
clinical features | 138 |
virus entry | 138 |
positive control | 138 |
innate immunity | 137 |
simplex virus | 137 |
respiratory viral | 137 |
fever virus | 137 |
mdck cells | 136 |
life technologies | 136 |
plasma membrane | 136 |
young children | 136 |
upper respiratory | 135 |
infection control | 135 |
results indicate | 135 |
cells expressing | 135 |
viral genome | 135 |
health system | 134 |
clinical samples | 134 |
antibody responses | 133 |
fusion protein | 133 |
nile virus | 133 |
mortality rate | 132 |
gel electrophoresis | 132 |
post infection | 132 |
stranded rna | 131 |
transfected cells | 131 |
nucleocapsid protein | 131 |
santa cruz | 130 |
calculated using | 130 |
increased risk | 130 |
clinical symptoms | 130 |
nucleic acids | 130 |
human rhinovirus | 130 |
confidence intervals | 129 |
factors associated | 129 |
mass spectrometry | 129 |
inflammatory cytokines | 128 |
positive samples | 128 |
hours post | 127 |
depressive symptoms | 127 |
cell lysates | 127 |
specific antibodies | 127 |
regression analysis | 126 |
samples collected | 126 |
copies ml | 126 |
family members | 126 |
independent experiments | 126 |
syndrome virus | 126 |
incubation period | 125 |
new york | 125 |
class ii | 125 |
respiratory pathogens | 125 |
statistical analysis | 124 |
care workers | 124 |
viral titers | 124 |
see table | 122 |
similar results | 121 |
body weight | 121 |
blood samples | 121 |
open reading | 121 |
tract infection | 120 |
inflammatory response | 120 |
transcription factor | 120 |
bronchitis virus | 120 |
i ifn | 120 |
western blotting | 120 |
case definition | 119 |
new cases | 119 |
ill patients | 119 |
bone marrow | 119 |
wide range | 119 |
tested positive | 118 |
binding domain | 118 |
determined using | 118 |
lymph nodes | 117 |
infected cases | 117 |
virus particles | 117 |
staphylococcus aureus | 117 |
job crafting | 117 |
virus titers | 116 |
like illness | 116 |
disease transmission | 116 |
core protein | 116 |
cells infected | 115 |
measured using | 115 |
dna polymerase | 115 |
differentially expressed | 114 |
mortality rates | 114 |
mouse anti | 114 |
human papillomavirus | 114 |
distress syndrome | 114 |
growth rate | 114 |
per day | 114 |
infection rate | 113 |
blot analysis | 113 |
surveillance system | 112 |
weight loss | 112 |
animal care | 112 |
viral pathogens | 111 |
among children | 111 |
sequence analysis | 111 |
culture medium | 111 |
significantly associated | 111 |
results show | 111 |
mammalian cells | 110 |
predictive value | 110 |
emerging infectious | 110 |
data analysis | 110 |
data suggest | 109 |
antibody titers | 109 |
final concentration | 109 |
critical care | 109 |
one health | 109 |
recent study | 108 |
fusion proteins | 108 |
human influenza | 108 |
cancer patients | 107 |
cell proliferation | 107 |
two weeks | 106 |
buffered saline | 106 |
high prevalence | 106 |
respiratory failure | 106 |
cell viability | 105 |
plaque assay | 105 |
sequence alignment | 105 |
clinical data | 105 |
first time | 105 |
median age | 105 |
among patients | 105 |
converting enzyme | 105 |
sars cov | 105 |
san diego | 104 |
days post | 104 |
table shows | 104 |
genomic dna | 104 |
significant increase | 104 |
enveloped viruses | 103 |
like particles | 103 |
per well | 103 |
transgenic mice | 103 |
animal models | 103 |
signaling pathways | 103 |
viral shedding | 103 |
secondary antibody | 103 |
review board | 103 |
genetic diversity | 103 |
exponential growth | 103 |
adaptive immune | 102 |
binding sites | 102 |
molecular weight | 102 |
risk perception | 102 |
cell fusion | 101 |
cell cultures | 101 |
host cells | 100 |
protein levels | 100 |
control strategies | 100 |
cell epitopes | 100 |
cytokine production | 100 |
pathogenic avian | 100 |
primary care | 100 |
nervous system | 100 |
pg ml | 99 |
well plate | 99 |
vesicular stomatitis | 99 |
necrosis factor | 99 |
infectious virus | 99 |
human respiratory | 98 |
study population | 98 |
conjugated anti | 98 |
also showed | 98 |
future studies | 98 |
electron microscopy | 98 |
tissue culture | 98 |
heart rate | 98 |
one study | 98 |
oxidative stress | 97 |
ns protein | 97 |
maximum likelihood | 97 |
cancer cells | 97 |
healthcare workers | 97 |
pcr assays | 97 |
widely used | 97 |
higher risk | 96 |
recent studies | 96 |
confirmed covid | 96 |
binding protein | 96 |
lysis buffer | 96 |
phylogenetic tree | 96 |
influenza surveillance | 96 |
institutional review | 96 |
linear regression | 96 |
three different | 96 |
case fatality | 95 |
attack rate | 95 |
immune cells | 95 |
written informed | 95 |
nipah virus | 95 |
reactive protein | 94 |
expressing cells | 94 |
mouse igg | 94 |
hemorrhagic fever | 94 |
pichia pastoris | 94 |
average number | 94 |
genome sequence | 94 |
analysis using | 94 |
total population | 94 |
human rights | 94 |
bat species | 94 |
viral loads | 94 |
infected animals | 94 |
hospital admission | 94 |
animal model | 93 |
mean age | 93 |
stomatitis virus | 93 |
shannon entropy | 93 |
signaling pathway | 93 |
transmission dynamics | 93 |
health status | 93 |
primer pairs | 93 |
mononuclear cells | 93 |
protein kinase | 92 |
data set | 92 |
specific antibody | 92 |
alveolar macrophages | 92 |
also used | 92 |
quantitative pcr | 92 |
complete genome | 92 |
severe covid | 91 |
bd biosciences | 91 |
dependent rna | 91 |
virus detection | 91 |
protein interactions | 91 |
within days | 91 |
positive cells | 91 |
target cells | 91 |
cell response | 91 |
receptor binding | 91 |
parainfluenza virus | 91 |
endothelial cells | 91 |
dependent manner | 90 |
bal fluid | 90 |
symptom onset | 90 |
mm edta | 90 |
general practice | 90 |
respiratory samples | 90 |
three independent | 90 |
exact test | 90 |
pulmonary disease | 90 |
virus strains | 90 |
small number | 90 |
spike glycoprotein | 89 |
small intestine | 89 |
associated case | 89 |
hand hygiene | 89 |
hela cells | 89 |
deep sequencing | 89 |
rabbit anti | 89 |
primer sets | 89 |
encephalitis virus | 89 |
saudi arabia | 89 |
risk assessment | 88 |
confidence interval | 88 |
significantly reduced | 88 |
primer set | 88 |
nasal mucosa | 88 |
reading frame | 88 |
viral protein | 88 |
endoplasmic reticulum | 88 |
much higher | 87 |
master mix | 87 |
culture supernatants | 87 |
leading edge | 87 |
serial interval | 87 |
membrane protein | 87 |
tumor necrosis | 87 |
th cells | 86 |
rna extraction | 86 |
acid sequence | 86 |
financial resources | 86 |
day post | 86 |
cell entry | 86 |
least two | 86 |
porcine circovirus | 86 |
machine learning | 85 |
clinical isolates | 85 |
genbank accession | 85 |
central nervous | 85 |
developing countries | 85 |
pcr system | 85 |
cells transfected | 84 |
statistical analyses | 84 |
rna synthesis | 84 |
daily wage | 84 |
whole blood | 84 |
critical role | 84 |
close contacts | 84 |
bacterial infection | 84 |
basic reproduction | 84 |
low levels | 83 |
detected using | 83 |
continuous variables | 83 |
pcr amplification | 83 |
ace expression | 83 |
vaccinated animals | 83 |
may lead | 83 |
less likely | 83 |
rhesus macaques | 83 |
population density | 83 |
zika ns | 83 |
results obtained | 82 |
commercially available | 82 |
severe pneumonia | 82 |
disease progression | 82 |
fatality rate | 82 |
envelope glycoprotein | 82 |
synonymous codon | 82 |
fetal bovine | 82 |
bacterial infections | 82 |
swine fever | 82 |
better understanding | 82 |
considered statistically | 82 |
nucleotide sequences | 82 |
data indicate | 82 |
disaster medicine | 82 |
streptococcus pneumoniae | 82 |
also reported | 82 |
sore throat | 81 |
also known | 81 |
tlr signaling | 81 |
early stage | 81 |
agarose gel | 81 |
per year | 81 |
health professionals | 81 |
leukemia virus | 81 |
airway epithelial | 81 |
treated mice | 81 |
human anti | 81 |
positive patients | 81 |
japanese encephalitis | 81 |
negative controls | 81 |
thank dr | 81 |
carbon emissions | 81 |
virus disease | 80 |
several studies | 80 |
chronic obstructive | 80 |
commonly used | 80 |
proinflammatory cytokines | 80 |
vp vp | 80 |
study showed | 79 |
reproductive number | 79 |
obstructive pulmonary | 79 |
epithelial cell | 79 |
mycobacterium tuberculosis | 79 |
molecular epidemiology | 79 |
regression model | 79 |
step rt | 79 |
like receptors | 79 |
mouth disease | 79 |
detection rate | 79 |
lymph node | 78 |
positive selection | 78 |
older adults | 78 |
mrna levels | 78 |
relatively high | 78 |
disease outbreaks | 78 |
coronavirus infection | 78 |
protective immunity | 78 |
reverse genetics | 78 |
metabolic pathway | 78 |
dna viruses | 78 |
nh cl | 78 |
south korea | 78 |
viral particles | 78 |
transcription factors | 78 |
different types | 78 |
thermo scientific | 77 |
may play | 77 |
patients infected | 77 |
pcr product | 77 |
expression level | 77 |
viral titer | 77 |
income countries | 77 |
molecular characterization | 77 |
aged years | 77 |
serial dilutions | 77 |
swine influenza | 77 |
luciferase activity | 77 |
normalized shannon | 77 |
high level | 77 |
cell membrane | 77 |
ge healthcare | 77 |
ch jx | 76 |
type vwd | 76 |
prospective study | 76 |
heart disease | 76 |
infected people | 76 |
previous reports | 76 |
adult patients | 76 |
free energy | 76 |
specific primers | 76 |
i interferon | 76 |
kindly provided | 75 |
analysis showed | 75 |
first case | 75 |
inflammatory responses | 75 |
chikungunya virus | 75 |
social networks | 75 |
assessed using | 75 |
respiratory diseases | 75 |
time reverse | 75 |
conducted using | 75 |
policy makers | 74 |
previously published | 74 |
child policy | 74 |
infectious agents | 74 |
randomly selected | 74 |
disease burden | 74 |
time period | 74 |
cleavage site | 74 |
ha protein | 74 |
high viral | 74 |
clinical trials | 74 |
standard curve | 73 |
obtained using | 73 |
early stages | 73 |
associated pneumonia | 73 |
per capita | 73 |
data elements | 73 |
existing immunity | 73 |
cells per | 73 |
rna virus | 73 |
fold higher | 73 |
life cycle | 72 |
washed three | 72 |
recent years | 72 |
medium containing | 72 |
nasopharyngeal swabs | 72 |
regression models | 72 |
ifitm proteins | 72 |
wild birds | 72 |
cells using | 72 |
nitric oxide | 72 |
adenovirus type | 72 |
case study | 72 |
first two | 72 |
severe respiratory | 72 |
horseradish peroxidase | 72 |
one day | 72 |
virus rna | 72 |
nucleotide sequence | 72 |
children aged | 71 |
body temperature | 71 |
infection among | 71 |
early detection | 71 |
sequence identity | 71 |
full length | 71 |
viet nam | 71 |
induced apoptosis | 71 |
plasmodium falciparum | 71 |
lung tissue | 71 |
protein synthesis | 71 |
global health | 71 |
immune function | 71 |
pcr reactions | 70 |
false positive | 70 |
inhibitory effect | 70 |
north america | 70 |
population size | 70 |
internal control | 70 |
genome sequences | 70 |
signal transduction | 70 |
stop codon | 70 |
united kingdom | 70 |
way anova | 70 |
protease inhibitor | 70 |
total protein | 69 |
health emergency | 69 |
first step | 69 |
prp sc | 69 |
standard deviations | 69 |
human adenovirus | 69 |
host response | 69 |
ntp managers | 69 |
hiv infection | 69 |
secondary antibodies | 69 |
surfactant protein | 69 |
hepatitis virus | 68 |
test results | 68 |
genomic rna | 68 |
treated cells | 68 |
culture supernatant | 68 |
social network | 68 |
syndromic surveillance | 68 |
sybr green | 68 |
envelope protein | 68 |
categorical variables | 68 |
crystal structures | 68 |
human cells | 68 |
antiviral drugs | 67 |
alexa fluor | 67 |
blood cells | 67 |
cells treated | 67 |
surveillance data | 67 |
hubei province | 67 |
clinical practice | 67 |
fold change | 67 |
cd cells | 67 |
medical students | 67 |
national institute | 67 |
pcr amplicons | 67 |
protective equipment | 67 |
acid residues | 67 |
study found | 67 |
mini kit | 67 |
may provide | 67 |
plasmid dna | 67 |
spotted hyenas | 67 |
primer pair | 67 |
heart failure | 67 |
chronic hepatitis | 67 |
capsid protein | 67 |
conformational changes | 67 |
virus strain | 66 |
older age | 66 |
reaction mixture | 66 |
analysis revealed | 66 |
plasma samples | 66 |
influenza season | 66 |
graphpad prism | 66 |
inflammatory cytokine | 66 |
knee height | 66 |
within hours | 66 |
acid composition | 66 |
psychological distress | 66 |
protein structure | 66 |
fruit bats | 66 |
transmissible gastroenteritis | 66 |
copy number | 66 |
adaptive immunity | 66 |
also detected | 65 |
three days | 65 |
honey bee | 65 |
tcid ml | 65 |
two major | 65 |
multiple sclerosis | 65 |
analysis tools | 65 |
likely due | 65 |
cell epitope | 65 |
ang ii | 65 |
psychological impact | 65 |
mouse monoclonal | 65 |
negative affect | 65 |
square test | 65 |
liver disease | 65 |
viral envelope | 65 |
correlation coefficient | 65 |
sensitivity analysis | 65 |
generated using | 64 |
personal protective | 64 |
tcad regimen | 64 |
terminal domain | 64 |
also identified | 64 |
plate reader | 64 |
sectional study | 64 |
interquartile range | 64 |
primary human | 64 |
results indicated | 64 |
csn ko | 64 |
small sample | 64 |
pcr using | 64 |
better understand | 64 |
simultaneous detection | 64 |
behavioral guidelines | 64 |
usage bias | 64 |
fisher scientific | 64 |
clinical specimens | 64 |
may reflect | 63 |
findings suggest | 63 |
free water | 63 |
reported cases | 63 |
blood cell | 63 |
epitope mapping | 63 |
pro complex | 63 |
may help | 63 |
close contact | 63 |
antiviral therapy | 63 |
relatively low | 63 |
accession number | 63 |
type diabetes | 63 |
mice immunized | 63 |
cleavage sites | 63 |
virus transmission | 63 |
infection rates | 63 |
washed twice | 63 |
bronchial epithelial | 63 |
infected cell | 63 |
human cd | 63 |
health services | 63 |
expression vector | 63 |
protein sequences | 62 |
neural network | 62 |
like protease | 62 |
ns protease | 62 |
pcr reaction | 62 |
multiplex pcr | 62 |
positive cases | 62 |
phylogenetic trees | 62 |
acute lung | 62 |
use committee | 62 |
diabetes mellitus | 62 |
recombination events | 62 |
data sets | 62 |
demographic characteristics | 61 |
female flowers | 61 |
specific igg | 61 |
inclusion criteria | 61 |
antigen expression | 61 |
glucose uptake | 61 |
may contribute | 61 |
binding affinity | 61 |
control study | 61 |
cdna library | 61 |
classical swine | 61 |
dendritic cell | 61 |
significant effect | 61 |
severe influenza | 61 |
red blood | 61 |
technical assistance | 61 |
rna replication | 61 |
infections among | 61 |
acid sequences | 61 |
membrane proteins | 61 |
igg antibody | 61 |
case patient | 61 |
cellular proteins | 61 |
patients admitted | 60 |
previous work | 60 |
cell signaling | 60 |
relatively small | 60 |
fusion activity | 60 |
pbs containing | 60 |
coding region | 60 |
patients hospitalized | 60 |
gene sequences | 60 |
conspiracy theories | 60 |
animal health | 60 |
molecular docking | 60 |
lung airways | 60 |
clinical outcomes | 60 |
dna sequencing | 60 |
principal findings | 60 |
expression patterns | 60 |
urban areas | 60 |
national health | 60 |
surveillance systems | 60 |
accession numbers | 60 |
fold increase | 60 |
differential expression | 60 |
also included | 60 |
lesser extent | 60 |
cdna synthesis | 60 |
tissue samples | 60 |
sentinel surveillance | 60 |
performed according | 60 |
large numbers | 60 |
polyacrylamide gel | 60 |
results demonstrate | 60 |
febrile neutropenia | 59 |
positive correlation | 59 |
pneumonia cases | 59 |
viral clearance | 59 |
based vaccine | 59 |
diagnostic accuracy | 59 |
increased levels | 59 |
using real | 59 |
sequence data | 59 |
quality control | 59 |
primary antibodies | 59 |
viral respiratory | 59 |
pedv strains | 59 |
reproduction numbers | 59 |
host immune | 59 |
multiple sequence | 59 |
wt mice | 59 |
cells well | 59 |
available data | 59 |
early phase | 59 |
rabbit igg | 59 |
antiviral response | 59 |
gene ontology | 59 |
translation initiation | 58 |
climate change | 58 |
ft dm | 58 |
negative binomial | 58 |
higher level | 58 |
univariate analysis | 58 |
acute phase | 58 |
southeast asia | 58 |
mm hepes | 58 |
disease outbreak | 58 |
serum albumin | 58 |
increased expression | 58 |
five years | 58 |
sari cases | 58 |
control cells | 58 |
university hospital | 58 |
bl mice | 58 |
virus release | 58 |
comparative analysis | 58 |
protein sequence | 58 |
coronavirus spike | 58 |
mouse hepatitis | 58 |
bat irf | 58 |
vaccine development | 57 |
respiratory specimens | 57 |
purified using | 57 |
evaluated using | 57 |
clinical presentation | 57 |
sir model | 57 |
rad np | 57 |
based assay | 57 |
false negative | 57 |
binding activity | 57 |
hcv ns | 57 |
social contacts | 57 |
host defense | 57 |
rna genome | 57 |
ko mice | 57 |
different species | 57 |
patients aged | 57 |
chest ct | 57 |
new world | 57 |
hendra virus | 57 |
mathematical models | 57 |
global burden | 57 |
much lower | 57 |
pathway classes | 56 |
suspected cases | 56 |
odds ratio | 56 |
sialic acid | 56 |
rsv infection | 56 |
ribosomal frameshifting | 56 |
spinal cord | 56 |
missing data | 56 |
fecal samples | 56 |
cellular immune | 56 |
household members | 56 |
specimen collection | 56 |
tumor cells | 56 |
data collected | 56 |
cell activation | 56 |
viral etiology | 56 |
data dictionary | 56 |
least three | 56 |
new zealand | 56 |
forward primer | 56 |
medical staff | 56 |
cell growth | 56 |
acute lower | 56 |
mice infected | 56 |
attack rates | 56 |
treatment groups | 56 |
sample collection | 56 |
frequently detected | 56 |
incubated overnight | 56 |
subcellular localization | 55 |
also performed | 55 |
observational study | 55 |
canine distemper | 55 |
human igg | 55 |
pneumonia patients | 55 |
mycoplasma pneumoniae | 55 |
negative predictive | 55 |
significant association | 55 |
bursal disease | 55 |
hospital beds | 55 |
study provides | 55 |
different time | 55 |
medical personnel | 55 |
case definitions | 55 |
retrospective study | 55 |
first report | 55 |
infectious bursal | 55 |
nested pcr | 55 |
per group | 55 |
studies reported | 55 |
negative correlation | 55 |
year old | 55 |
molecular mechanisms | 55 |
expression plasmids | 55 |
close proximity | 55 |
health authorities | 55 |
high degree | 55 |
cell subsets | 55 |
epidermal growth | 55 |
investigate whether | 55 |
cholesterol efflux | 55 |
novel influenza | 55 |
protein interaction | 55 |
study also | 55 |
previously shown | 55 |
inflammatory cells | 55 |
heat shock | 54 |
emergency department | 54 |
acid substitutions | 54 |
negative results | 54 |
viral detection | 54 |
pilot study | 54 |
contributed reagents | 54 |
cumulative number | 54 |
million people | 54 |
human airway | 54 |
quantified using | 54 |
seven days | 54 |
reading frames | 54 |
materials analysis | 54 |
study design | 54 |
ic values | 54 |
ns activated | 54 |
viral pneumonia | 54 |
may result | 54 |
von willebrand | 54 |
nasal swabs | 54 |
exhaled breath | 54 |
immunosorbent assay | 54 |
primary cells | 54 |
clinical course | 54 |
fatal cases | 54 |
reagents materials | 54 |
proteolytic cleavage | 54 |
medical resources | 54 |
among different | 54 |
days pi | 54 |
march th | 54 |
influenza epidemics | 54 |
protein concentration | 54 |
severe illness | 53 |
plasma levels | 53 |
cruz biotechnology | 53 |
also shown | 53 |
descriptive statistics | 53 |
breast cancer | 53 |
sars spike | 53 |
detection rates | 53 |
positive results | 53 |
kcal mol | 53 |
positive predictive | 53 |
diagnostic tests | 53 |
cotton rats | 53 |
middle ear | 53 |
expression profiles | 53 |
rapid detection | 53 |
regulatory factor | 53 |
oseltamivir carboxylate | 53 |
future research | 53 |
cultured cells | 53 |
personality traits | 53 |
one patient | 53 |
confirmed case | 53 |
dengue fever | 53 |
influenza transmission | 53 |
factors influencing | 53 |
bronchoalveolar lavage | 52 |
nuclear export | 52 |
dna vaccine | 52 |
ct values | 52 |
results suggested | 52 |
severe group | 52 |
effective reproduction | 52 |
allowed us | 52 |
igg antibodies | 52 |
klebsiella pneumoniae | 52 |
virus ns | 52 |
per ml | 52 |
start codon | 52 |
human lung | 52 |
newcastle disease | 52 |
mm dtt | 52 |
strongly associated | 52 |
secondary cases | 52 |
medical records | 52 |
reporter gene | 52 |
mm mgcl | 52 |
infected children | 52 |
hospital mortality | 52 |
infectious period | 52 |
binding proteins | 52 |
one year | 52 |
case report | 52 |
clinical trial | 52 |
calf serum | 52 |
cancer cell | 52 |
term care | 52 |
human cytomegalovirus | 52 |
asymptomatic infections | 52 |
studies showed | 52 |
buffer containing | 52 |
constructed using | 52 |
cases per | 51 |
directed mutagenesis | 51 |
test whether | 51 |
post transfection | 51 |
derived macrophages | 51 |
medical center | 51 |
virus isolation | 51 |
intellectual capital | 51 |
gb virus | 51 |
serially diluted | 51 |
body mass | 51 |
likelihood ratio | 51 |
empty vector | 51 |
error bars | 51 |
virus glycoprotein | 51 |
outbreak size | 51 |
pseudoknot rna | 51 |
using data | 51 |
clinically relevant | 51 |
reverse primer | 51 |
model selection | 51 |
ms ms | 51 |
different concentrations | 51 |
different countries | 51 |
circovirus type | 51 |
genes involved | 51 |
sars outbreak | 51 |
fluorescence microscopy | 51 |
cell type | 51 |
remains unclear | 50 |
tube assay | 50 |
viral co | 50 |
cd dpp | 50 |
bmnpv infection | 50 |
prrsv infection | 50 |
institutional animal | 50 |
high affinity | 50 |
ace mrna | 50 |
single infections | 50 |
rural areas | 50 |
isolated ns | 50 |
helicobacter pylori | 50 |
conjugated goat | 50 |
medical research | 50 |
small molecule | 50 |
pd deficiency | 50 |
associated coronavirus | 50 |
rna binding | 50 |
culture media | 50 |
strand rna | 50 |
origin influenza | 50 |
bluetongue virus | 50 |
transmission rate | 50 |
otitis media | 50 |
high mortality | 50 |
high sensitivity | 50 |
may represent | 50 |
human rhinoviruses | 50 |
one week | 50 |
virtual screening | 50 |
transmission mitigation | 50 |
human serum | 50 |
also tested | 50 |
tgev infection | 50 |
zika virus | 50 |
thermo fisher | 50 |
orf gene | 49 |
using primers | 49 |
well known | 49 |
blood mononuclear | 49 |
many countries | 49 |
patients without | 49 |
optical density | 49 |
mediated immune | 49 |
humoral immune | 49 |
surface expression | 49 |
containing mm | 49 |
long term | 49 |
protective immune | 49 |
human cases | 49 |
significant reduction | 49 |
study using | 49 |
model fit | 49 |
assay kit | 49 |
publicly available | 49 |
specific immune | 49 |
assessment tools | 49 |
mean values | 49 |
expressed genes | 49 |
host factors | 49 |
psychometric properties | 49 |
molecular biology | 49 |
human capital | 49 |
lung disease | 49 |
molecular dynamics | 49 |
biothreat assay | 49 |
naturally infected | 49 |
protease inhibitors | 49 |
human plasma | 49 |
controlled trial | 49 |
data element | 49 |
mitigation behavioral | 49 |
one hour | 49 |
first study | 49 |
er stress | 49 |
software package | 49 |
ai ml | 49 |
bat cell | 49 |
chikv ls | 49 |
yeast cells | 48 |
using anti | 48 |
virus challenge | 48 |
mouse models | 48 |
uric acid | 48 |
murine coronavirus | 48 |
protein binding | 48 |
human subjects | 48 |
polyclonal antibody | 48 |
findings indicate | 48 |
influenza activity | 48 |
linear epitopes | 48 |
pfu ml | 48 |
dependent variable | 48 |
pediatric patients | 48 |
neutralizing activity | 48 |
preventive behavior | 48 |
pcr kit | 48 |
multivariate analysis | 48 |
recombinant adenovirus | 48 |
ibv pseudoknot | 48 |
novel human | 48 |
human monoclonal | 48 |
resistant staphylococcus | 48 |
host proteins | 48 |
risk communication | 48 |
two independent | 48 |
viral fusion | 48 |
small molecules | 48 |
control mice | 48 |
bacterial pneumonia | 48 |
three weeks | 48 |
medical care | 48 |
cell population | 48 |
phosphate dehydrogenase | 48 |
healthcare system | 48 |
another study | 47 |
several limitations | 47 |
broad spectrum | 47 |
fatty acid | 47 |
cytopathic effect | 47 |
transport medium | 47 |
cell populations | 47 |
cells showed | 47 |
rabbit polyclonal | 47 |
control groups | 47 |
i ifns | 47 |
bac bsi | 47 |
wildlife rehabilitation | 47 |
statistical complexity | 47 |
secondary structures | 47 |
influenza outbreaks | 47 |
infection may | 47 |
three groups | 47 |
monoclonal anti | 47 |
molecular detection | 47 |
coa racemase | 47 |
pedv outbreak | 47 |
total volume | 47 |
replication cycle | 47 |
reference strains | 47 |
stem cell | 47 |
children hospitalized | 47 |
ms patients | 47 |
antigen presentation | 47 |
disease spread | 47 |
fluorescence intensity | 47 |
bsi assay | 47 |
high throughput | 47 |
primary antibody | 47 |
linked immunosorbent | 47 |
antiviral responses | 47 |
odds ratios | 47 |
microwave heating | 47 |
across different | 46 |
among hospitalized | 46 |
growth medium | 46 |
immunized mice | 46 |
modified vaccinia | 46 |
nonstructural protein | 46 |
standard error | 46 |
whole genome | 46 |
leading cause | 46 |
affinity chromatography | 46 |
tract disease | 46 |
cell migration | 46 |
low ph | 46 |
host species | 46 |
single cell | 46 |
immunofluorescence assay | 46 |
protein stability | 46 |
different regions | 46 |
yellow fever | 46 |
recombinant human | 46 |
new england | 46 |
data using | 46 |
cell monolayers | 46 |
nk cell | 46 |
terminal region | 46 |
femoral head | 46 |
viruses isolated | 46 |
patient care | 46 |
culture collection | 46 |
reference strain | 46 |
enzyme activity | 46 |
plasma cells | 46 |
qiastat rp | 46 |
human health | 46 |
contact patterns | 46 |
nuclear factor | 46 |
vast majority | 46 |
wearing masks | 46 |
hospital stay | 46 |
care facilities | 46 |
crucial role | 46 |
clinical manifestations | 46 |
wild animals | 46 |
index case | 46 |
retrospective cohort | 46 |
decision making | 46 |
experimental groups | 46 |
human coronaviruses | 46 |
estimated using | 45 |
disease surveillance | 45 |
sample sizes | 45 |
broad range | 45 |
internal consistency | 45 |
research team | 45 |
acid extraction | 45 |
considered significant | 45 |
bat cells | 45 |
much less | 45 |
specific primer | 45 |
adverse events | 45 |
lung cancer | 45 |
protective effect | 45 |
distancing measures | 45 |
health interventions | 45 |
threatened species | 45 |
european countries | 45 |
matrix protein | 45 |
blood pressure | 45 |
graphpad software | 45 |
peste des | 45 |
coding sequences | 45 |
nursing homes | 45 |
observational studies | 45 |
family member | 45 |
clinical severity | 45 |
surface display | 45 |
expression system | 45 |
amniotic fluid | 45 |
liquid chromatography | 45 |
influenza vaccines | 45 |
human transmission | 45 |
guinea pigs | 45 |
specific binding | 45 |
significantly decreased | 45 |
reported previously | 45 |
influenza cases | 45 |
virus genome | 45 |
cell counts | 45 |
amplified using | 45 |
lower levels | 45 |
coping appraisal | 45 |
coronavirus infectious | 45 |
icu admission | 45 |
study conducted | 45 |
fusion peptide | 45 |
petits ruminants | 44 |
severe dengue | 44 |
visualized using | 44 |
influenza infections | 44 |
done using | 44 |
quantitative real | 44 |
also thank | 44 |
protease cleavage | 44 |
confocal microscopy | 44 |
cell receptor | 44 |
cd expression | 44 |
major histocompatibility | 44 |
symptomatic patients | 44 |
fetal calf | 44 |
des petits | 44 |
conserved among | 44 |
firefly luciferase | 44 |
raw data | 44 |
coronavirus pneumonia | 44 |
dengue infection | 44 |
coronavirus infections | 44 |
correlation analysis | 44 |
statistical computing | 44 |
previous research | 44 |
three viruses | 44 |
data obtained | 44 |
two patients | 44 |
foster city | 44 |
parameter values | 44 |
iridica bac | 44 |
two distinct | 44 |
evolutionary genetics | 44 |
north american | 44 |
causative agent | 44 |
virus shedding | 44 |
experimental data | 44 |
age distribution | 44 |
experimentally infected | 44 |
face masks | 44 |
central role | 44 |
clinical disease | 44 |
natural history | 44 |
web server | 44 |
surgical masks | 44 |
highly sensitive | 44 |
isothermal amplification | 44 |
collected data | 44 |
related genes | 44 |
first reported | 44 |
ifn response | 43 |
infectious peritonitis | 43 |
positive effect | 43 |
chronic conditions | 43 |
hek cells | 43 |
viral nucleic | 43 |
two years | 43 |
demographic data | 43 |
written consent | 43 |
bacterial pathogens | 43 |
vaccination status | 43 |
may affect | 43 |
young adults | 43 |
two studies | 43 |
care units | 43 |
blocking buffer | 43 |
normal distribution | 43 |
patients receiving | 43 |
drug discovery | 43 |
functional analysis | 43 |
molecular methods | 43 |
severe clinical | 43 |
one another | 43 |
protein folding | 43 |
key role | 43 |
pao fio | 43 |
feline infectious | 43 |
ml penicillin | 43 |
cardiovascular disease | 43 |
syncytia formation | 43 |
health behaviors | 43 |
inhibitory activity | 43 |
information criterion | 43 |
vaccination coverage | 43 |
epidemiological data | 43 |
data demonstrate | 43 |
i molecules | 43 |
highest number | 43 |
dt cells | 43 |
positive rate | 43 |
kcnq kcne | 43 |
mathematical model | 43 |
swab samples | 43 |
antiviral agents | 43 |
mcmv infection | 43 |
longitudinal study | 43 |
pneumococcal pneumonia | 43 |
envelope proteins | 43 |
medium supplemented | 43 |
included studies | 43 |
human population | 43 |
investigated whether | 42 |
factor receptor | 42 |
data sharing | 42 |
containing mg | 42 |
goblet cells | 42 |
virus titer | 42 |
effect size | 42 |
phosphate buffer | 42 |
patients received | 42 |
supply chains | 42 |
health surveillance | 42 |
mild symptoms | 42 |
priority group | 42 |
may explain | 42 |
four times | 42 |
activated mazf | 42 |
edge pseudopod | 42 |
american type | 42 |
host responses | 42 |
one hand | 42 |
worth noting | 42 |
primer sequences | 42 |
pcr detection | 42 |
bacterial species | 42 |
daily basis | 42 |
transcription polymerase | 42 |
might also | 42 |
sectional survey | 42 |
potential role | 42 |
phosphate buffered | 42 |
stem cells | 42 |
clock genes | 42 |
software version | 42 |
viral antigen | 42 |
deficient mice | 42 |
increasing concentrations | 42 |
laboratory testing | 42 |
ct value | 42 |
asymptomatic individuals | 42 |
circular dichroism | 42 |
mainland china | 42 |
assess whether | 42 |
vaccination uptake | 42 |
primers used | 42 |
persistently infected | 41 |
higher prevalence | 41 |
blood culture | 41 |
coronavirus nucleocapsid | 41 |
outbreak risk | 41 |
clinical studies | 41 |
vaccine strain | 41 |
new coronavirus | 41 |
genome sequencing | 41 |
margarita strain | 41 |
virus production | 41 |
insect cells | 41 |
influenza outbreak | 41 |
structural capital | 41 |
coronavirus associated | 41 |
induced cell | 41 |
reference sequence | 41 |
natural killer | 41 |
tested whether | 41 |
mers pseudovirions | 41 |
white blood | 41 |
also demonstrated | 41 |
economic losses | 41 |
virus antigen | 41 |
data show | 41 |
household size | 41 |
regression analyses | 41 |
image analysis | 41 |
essential role | 41 |
limited number | 41 |
secondary attack | 41 |
showed higher | 41 |
health systems | 41 |
extracted using | 41 |
slightly higher | 41 |
infection risk | 41 |
expression plasmid | 41 |
study group | 41 |
cells may | 41 |
coronavirus hku | 41 |
stranded dna | 41 |
molecular cloning | 41 |
cervical cancer | 41 |
general public | 41 |
mtb infection | 41 |
took place | 41 |
mean value | 41 |
biofilm formation | 40 |
many studies | 40 |
study suggests | 40 |
corona virus | 40 |
observation period | 40 |
reactive oxygen | 40 |
cov spike | 40 |
gene sequence | 40 |
septic shock | 40 |
host range | 40 |
respondents reported | 40 |
analysis indicated | 40 |
job demands | 40 |
willebrand factor | 40 |
expression profile | 40 |
angiotensin ii | 40 |
serum levels | 40 |
different cell | 40 |
common respiratory | 40 |
capsid proteins | 40 |
interferon regulatory | 40 |
based vaccines | 40 |
using two | 40 |
hcl ph | 40 |
study aimed | 40 |
described elsewhere | 40 |
study participants | 40 |
quantitative rt | 40 |
based elisa | 40 |
detection limit | 40 |
asymptomatic patients | 40 |
genome copies | 40 |
mutant protein | 40 |
may indicate | 40 |
false positives | 40 |
using standard | 40 |
sample buffer | 40 |
common cold | 40 |
forming units | 40 |
gc content | 40 |
transmembrane protein | 40 |
gastroenteritis virus | 40 |
molecular evolutionary | 40 |
low viral | 40 |
higher proportion | 40 |
structural protein | 40 |
illness severity | 40 |
two viruses | 40 |
ppe use | 40 |
pressure difference | 40 |
structural basis | 40 |
tested using | 40 |
cases admitted | 40 |
highly contagious | 40 |
ml streptomycin | 40 |
untranslated region | 40 |
right panel | 40 |
fold dilutions | 40 |
apoptotic cells | 39 |
time course | 39 |
important roles | 39 |
mortality among | 39 |
ha gene | 39 |
model parameters | 39 |
infected pigs | 39 |
literature review | 39 |
probability distribution | 39 |
two consecutive | 39 |
coronary artery | 39 |
clinical diagnosis | 39 |
mask wearing | 39 |
point scale | 39 |
vascular endothelial | 39 |
factors affecting | 39 |
respiratory rate | 39 |
replicase gene | 39 |
flow cytometer | 39 |
single nucleotide | 39 |
molecular modeling | 39 |
academic performance | 39 |
children years | 39 |
neutrophil count | 39 |
also significantly | 39 |
major cause | 39 |
canine coronavirus | 39 |
type culture | 39 |
training set | 39 |
following infection | 39 |
vaccine candidates | 39 |
live poultry | 39 |
health workers | 39 |
multivariate logistic | 39 |
societal learning | 39 |
protein assay | 39 |
drug resistance | 39 |
expression data | 39 |
normal control | 39 |
studies suggest | 39 |
message retransmission | 39 |
possibly due | 39 |
novel virus | 39 |
systematic reviews | 39 |
haemorrhagic fever | 39 |
histocompatibility complex | 39 |
ii cells | 39 |
communicable diseases | 39 |
serine protease | 39 |
kidney cells | 39 |
vero cell | 39 |
bacillus subtilis | 39 |
barr virus | 39 |
response rate | 39 |
customer capital | 39 |
coding sequence | 39 |
proteins involved | 39 |
fluorescence microscope | 39 |
base pairs | 39 |
randomized controlled | 39 |
side effects | 39 |
information products | 39 |
transmembrane domain | 39 |
two types | 38 |
studies using | 38 |
antigenic sites | 38 |
significantly less | 38 |
assay using | 38 |
congenital heart | 38 |
cytokine responses | 38 |
icu beds | 38 |
hcv hiv | 38 |
health service | 38 |
parainfluenza viruses | 38 |
cell leukemia | 38 |
pwa chip | 38 |
medical history | 38 |
corrected chi | 38 |
may increase | 38 |
nsir model | 38 |
mice showed | 38 |
examine whether | 38 |
multiplex real | 38 |
dna fragments | 38 |
reverse primers | 38 |
clinical outcome | 38 |
two days | 38 |
naturally occurring | 38 |
individual differences | 38 |
fed calves | 38 |
clinical information | 38 |
gaen api | 38 |
antibody levels | 38 |
fluorescent protein | 38 |
monte carlo | 38 |
copies per | 38 |
deaths per | 38 |
viral transmission | 38 |
particle size | 38 |
shannon divergence | 38 |
positive controls | 38 |
neural networks | 38 |
recognition receptors | 38 |
source region | 38 |
ifn signaling | 38 |
cured cases | 38 |
health outcomes | 38 |
distemper virus | 38 |
four different | 38 |
one virus | 38 |
methodology principal | 38 |
selection bias | 38 |
uninfected cells | 38 |
physical distancing | 38 |
borna disease | 38 |
duplex undp | 38 |
lung tissues | 38 |
significant decrease | 38 |
lentiviral vectors | 38 |
times higher | 38 |
requiring hospitalization | 38 |
cell wall | 37 |
published data | 37 |
viral dna | 37 |
data type | 37 |
research priorities | 37 |
viral diseases | 37 |
highly expressed | 37 |
nasopharyngeal swab | 37 |
flow rate | 37 |
among adults | 37 |
hadv pneumonia | 37 |
roche diagnostics | 37 |
outbreak detection | 37 |
online survey | 37 |
huh cells | 37 |
wild hyenas | 37 |
chronic disease | 37 |
antigenic peptides | 37 |
confirmed influenza | 37 |
pcr testing | 37 |
electronic health | 37 |
type iii | 37 |
infections caused | 37 |
year period | 37 |
positively correlated | 37 |
low level | 37 |
university students | 37 |
cycle arrest | 37 |
viral spread | 37 |
studies conducted | 37 |
nutritional status | 37 |
nasal swab | 37 |
competency profile | 37 |
see also | 37 |
hiv aids | 37 |
tested negative | 37 |
pdm virus | 37 |
human pathogens | 37 |
virus hemagglutinin | 37 |
one third | 37 |
pcr primers | 37 |
life sciences | 37 |
catalytic activity | 37 |
influenza strains | 37 |
prepared using | 37 |
final model | 37 |
samples obtained | 37 |
alveolar epithelial | 37 |
op swabs | 37 |
vaccine dose | 37 |
assessment tool | 37 |
rna interference | 37 |
fatality rates | 37 |
ebov infection | 37 |
york city | 37 |
per cell | 37 |
showed similar | 37 |
household contacts | 37 |
pcr array | 37 |
whitney test | 37 |
mortality risk | 37 |
first week | 37 |
population dynamics | 37 |
high number | 37 |
rna mini | 37 |
pfu cell | 37 |
older children | 37 |
higher expression | 37 |
phylogenetic analyses | 37 |
five days | 37 |
binding buffer | 36 |
severe symptoms | 36 |
selected aptamers | 36 |
main protease | 36 |
plesiomonas shigelloides | 36 |
virus ankara | 36 |
flow cytometric | 36 |
growth rates | 36 |
next generation | 36 |
bacillus anthracis | 36 |
gold standard | 36 |
mild cases | 36 |
exclusion criteria | 36 |
experimental infection | 36 |
luciferase reporter | 36 |
isg vs | 36 |
influenza seasons | 36 |
fluid intake | 36 |
next day | 36 |
study protocol | 36 |
conspiracy beliefs | 36 |
pathological changes | 36 |
coding regions | 36 |
adv pneumonia | 36 |
recently reported | 36 |
extraction kit | 36 |
useful tool | 36 |
health problems | 36 |
two months | 36 |
conclusions significance | 36 |
chv ns | 36 |
elisa kit | 36 |
mycobacterium avium | 36 |
coronavirus nl | 36 |
high proportion | 36 |
recombinant protein | 36 |
health impact | 36 |
human alveolar | 36 |
disulfide loop | 36 |
vp sequences | 36 |
positive affect | 36 |
study reported | 36 |
research center | 36 |
human genome | 36 |
iberian lynx | 36 |
mm sodium | 36 |
research ethics | 36 |
treated animals | 36 |
viral yield | 36 |
interstitial pneumonia | 36 |
yeast two | 36 |
ari patients | 36 |
identified using | 36 |
genetic variation | 36 |
pcr master | 36 |
flu severity | 36 |
data points | 36 |
vaccine strains | 36 |
cytokine levels | 36 |
type infection | 36 |
genetics analysis | 36 |
cell adhesion | 36 |
isolation room | 36 |
throughput screening | 36 |
pattern recognition | 36 |
control animals | 36 |
diagnostic methods | 36 |
mm nh | 36 |
spatial distribution | 36 |
previous report | 36 |
deep learning | 36 |
pneumonia among | 36 |
provide evidence | 36 |
hcv infection | 36 |
disease outcome | 36 |
primary outcome | 36 |
susceptible population | 35 |
viral infectivity | 35 |
healthy children | 35 |
genital tract | 35 |
lipid rafts | 35 |
overseas investment | 35 |
enzymatic activity | 35 |
distilled water | 35 |
restriction sites | 35 |
clinical care | 35 |
laboratory animal | 35 |
human disease | 35 |
tip cover | 35 |
qiaamp viral | 35 |
genbank database | 35 |
oxygen species | 35 |
sleep quality | 35 |
incidence rate | 35 |
host interactions | 35 |
generation time | 35 |
sialic acids | 35 |
codon positions | 35 |
nonstructural proteins | 35 |
high rate | 35 |
incidence rates | 35 |
ozone exposure | 35 |
usage patterns | 35 |
medical school | 35 |
high frequency | 35 |
household agents | 35 |
lung epithelial | 35 |
asymptomatic cases | 35 |
responses induced | 35 |
kidney injury | 35 |
laboratory animals | 35 |
cases reported | 35 |
highly infectious | 35 |
samples tested | 35 |
viral sequences | 35 |
thermal cycler | 35 |
ifitmdel animals | 35 |
fars province | 35 |
icu admissions | 35 |
laboratory confirmed | 35 |
many different | 35 |
cytokine storm | 35 |
community residents | 35 |
md simulations | 35 |
dna sequences | 35 |
cystic fibrosis | 35 |
lessons learned | 35 |
inflammatory cell | 35 |
mechanisms underlying | 35 |
antiviral drug | 35 |
ciri index | 35 |
equal volume | 35 |
vaccine design | 35 |
rabies virus | 35 |
liquid nitrogen | 35 |
may occur | 35 |
factor alpha | 35 |
ex vivo | 35 |
first day | 35 |
median time | 35 |
second wave | 35 |
significant impact | 35 |
null hypothesis | 35 |
target proteins | 35 |
avian infectious | 35 |
dehydrogenase deficiency | 35 |
adhesion molecule | 35 |
ace inhibitors | 35 |
visceral leishmaniasis | 35 |
justice minister | 35 |
sapovirus infection | 35 |
point mutations | 35 |
cell lysate | 35 |
harris county | 35 |
antibody binding | 35 |
results also | 35 |
iu ml | 35 |
human infection | 35 |
contact rate | 35 |
two main | 35 |
emerging viruses | 35 |
novo assembly | 35 |
secretory pathway | 35 |
expressed proteins | 35 |
expression analysis | 35 |
pcr results | 34 |
type virus | 34 |
scoping review | 34 |
newly identified | 34 |
strong evidence | 34 |
broadly neutralizing | 34 |
conspiracy theory | 34 |
big brown | 34 |
pseudomonas aeruginosa | 34 |
nelson bay | 34 |
latent infection | 34 |
coping style | 34 |
single amino | 34 |
recombinant scorpine | 34 |
viral disease | 34 |
using graphpad | 34 |
cause mortality | 34 |
rna isolation | 34 |
adverse effects | 34 |
may serve | 34 |
polyclonal antibodies | 34 |
human ifitm | 34 |
left panel | 34 |
viruses using | 34 |
well established | 34 |
infected pneumonia | 34 |
virus spread | 34 |
per person | 34 |
accessory proteins | 34 |
ipa infection | 34 |
cells ml | 34 |
time polymerase | 34 |
domestic cats | 34 |
haemophilus influenzae | 34 |
two proteins | 34 |
honey bees | 34 |
important factor | 34 |
death rates | 34 |
presenting cells | 34 |
bat activity | 34 |
first confirmed | 34 |
molecular probes | 34 |
like protein | 34 |
community acquired | 34 |
sequence similarity | 34 |
molecular diagnostics | 34 |
community transmission | 34 |
wide variety | 34 |
disease emergence | 34 |
preventative health | 34 |
linear epitope | 34 |
tat expression | 34 |
receptor expression | 34 |
patients tested | 34 |
induces apoptosis | 34 |
codon position | 34 |
significantly greater | 34 |
alpha beta | 34 |
consensus sequence | 34 |
pcr analysis | 34 |
high quality | 34 |
based surveillance | 34 |
currently available | 34 |
candida albicans | 34 |
risk groups | 34 |
healthy controls | 34 |
dna replication | 34 |
emergency room | 34 |
health agency | 34 |
grand island | 34 |
receptor signaling | 34 |
laboratory tests | 34 |
vaccine efficacy | 34 |
clinical isolate | 34 |
nursing home | 34 |
biological processes | 34 |
enteric viruses | 34 |
will help | 34 |
sari criteria | 34 |
american journal | 34 |
sequence alignments | 34 |
mutational analysis | 33 |
treatment group | 33 |
household level | 33 |
airway proteases | 33 |
negative samples | 33 |
febrile illness | 33 |
i site | 33 |
social interactions | 33 |
common marmosets | 33 |
intervention strategies | 33 |
health insurance | 33 |
transcript abundance | 33 |
rna extracted | 33 |
gene therapy | 33 |
based study | 33 |
opioid overdose | 33 |
water molecules | 33 |
virus neutralization | 33 |
different groups | 33 |
defective interfering | 33 |
different levels | 33 |
one month | 33 |
protein complexes | 33 |
plasma protein | 33 |
computed tomography | 33 |
antiviral treatment | 33 |
virus infected | 33 |
molecular analysis | 33 |
metabolic pathways | 33 |
multiplex rt | 33 |
little effect | 33 |
judicial independence | 33 |
located within | 33 |
late endosomes | 33 |
houttuynia cordata | 33 |
treatment suspensions | 33 |
bovine viral | 33 |
compared using | 33 |
clinical management | 33 |
per million | 33 |
drug design | 33 |
sense rna | 33 |
conjugated secondary | 33 |
investment risk | 33 |
gastrointestinal tract | 33 |
ion channel | 33 |
cells via | 33 |
throat swab | 33 |
unless otherwise | 33 |
results presented | 33 |
dnase i | 33 |
dromedary camels | 33 |
species transmission | 33 |
previously identified | 33 |
pandemic potential | 33 |
immunocompromised patients | 33 |
virus envelope | 33 |
independent variables | 33 |
pro domain | 33 |
reverse transcribed | 33 |
information regarding | 33 |
virus nucleoprotein | 33 |
persistent infection | 33 |
takes place | 33 |
laboratory data | 33 |
deaths due | 33 |
genetic analysis | 33 |
age years | 33 |
using different | 33 |
mitigation strategies | 33 |
vitro transcription | 33 |
structural features | 33 |
th percentile | 33 |
stool samples | 33 |
viral protease | 33 |
cd bs | 33 |
frameshifting efficiency | 33 |
eudoc program | 33 |
mule deer | 33 |
faecal virome | 33 |
sample preparation | 33 |
mutational pressure | 33 |
mammalian species | 33 |
stably expressing | 33 |
apt ndv | 33 |
lymphocyte count | 33 |
health event | 33 |
recurrent wheezing | 32 |
like particle | 32 |
page gel | 32 |
diagnostic performance | 32 |
acute kidney | 32 |
oxygen saturation | 32 |
initiation factor | 32 |
parameter estimates | 32 |
state university | 32 |
protein level | 32 |
competitive advantage | 32 |
prospective cohort | 32 |
different viruses | 32 |
infected person | 32 |
rhpiv ag | 32 |
healthcare professionals | 32 |
cryptic virus | 32 |
detection kit | 32 |
verbal autopsy | 32 |
patient samples | 32 |
rna samples | 32 |
based elisas | 32 |
infectious dose | 32 |
yersinia pestis | 32 |
liquid interface | 32 |
hepatocellular carcinoma | 32 |
pam cys | 32 |
lethal challenge | 32 |
myeloid cells | 32 |
research institute | 32 |
target protein | 32 |
study shows | 32 |
tumor growth | 32 |
signal peptide | 32 |
tract samples | 32 |
activated protein | 32 |
human resources | 32 |
ml pbs | 32 |
detection system | 32 |
spectrum antiviral | 32 |
human apobec | 32 |
values obtained | 32 |
south african | 32 |
attenuation level | 32 |
experimental conditions | 32 |
southern china | 32 |
unpublished data | 32 |
molar ratio | 32 |
acf policy | 32 |
resource allocation | 32 |
porcine respiratory | 32 |
one hundred | 32 |
rhinovirus infection | 32 |
point likert | 32 |
pcr conditions | 32 |
mg dl | 32 |
swine flu | 32 |
induced lung | 32 |
may cause | 32 |
ari cases | 32 |
dna extraction | 32 |
several different | 32 |
earlier studies | 32 |
throat swabs | 32 |
cell survival | 32 |
side chain | 32 |
pathogenic bacteria | 32 |
chronic fatigue | 32 |
cumulative incidence | 32 |
orf abc | 32 |
contigs singletons | 32 |
group showed | 32 |
authors thank | 32 |
primary health | 32 |
alveolar type | 32 |
respiratory illnesses | 32 |
first days | 32 |
disease caused | 32 |
rank test | 32 |
days prior | 32 |
perceived effectiveness | 32 |
study included | 32 |
hemagglutination inhibition | 32 |
mice exhibited | 32 |
uncleavable mazf | 32 |
clinical microbiology | 32 |
abdominal muscle | 32 |
symptoms among | 32 |
ipv du | 32 |
old world | 32 |
derived peptides | 32 |
rrna gene | 32 |
jurkat cells | 32 |
showed significant | 32 |
surface proteins | 32 |
domestic animals | 32 |
sendai virus | 32 |
proinflammatory cytokine | 32 |
systematic analysis | 32 |
library construction | 32 |
multiple comparisons | 32 |
ic value | 32 |
kda protein | 32 |
among pregnant | 32 |
social distance | 32 |
target sequence | 32 |
acid changes | 32 |
cov infections | 32 |
also examined | 32 |
dna virus | 32 |
epidemiological studies | 32 |
dengue patients | 32 |
quantitative analysis | 31 |
serum sample | 31 |
negative effect | 31 |
antiviral defense | 31 |
diseases society | 31 |
dna polymerases | 31 |
expression pattern | 31 |
th responses | 31 |
fatigue syndrome | 31 |
cd ra | 31 |
icu data | 31 |
rpmi medium | 31 |
mammalian cell | 31 |
clinical research | 31 |
loaded onto | 31 |
er membrane | 31 |
loading control | 31 |
dna vaccines | 31 |
nuclear import | 31 |
cd lymphocytes | 31 |
also investigated | 31 |
energy consumption | 31 |
two strains | 31 |
murine model | 31 |
probably due | 31 |
test result | 31 |
children less | 31 |
recently described | 31 |
significant changes | 31 |
vvibdv strains | 31 |
peb gf | 31 |
molecular basis | 31 |
new insights | 31 |
vaccine uptake | 31 |
antibody production | 31 |
bovine respiratory | 31 |
support vector | 31 |
cell count | 31 |
cellular immunity | 31 |
nose syndrome | 31 |
observed among | 31 |
producing cells | 31 |
epidemiological parameters | 31 |
confocal microscope | 31 |
mm kcl | 31 |
hiv co | 31 |
viral agents | 31 |
county level | 31 |
data sources | 31 |
models using | 31 |
cov rna | 31 |
wbc count | 31 |
cytokine expression | 31 |
higher values | 31 |
data showed | 31 |
stool suspensions | 31 |
mer peptides | 31 |
highest risk | 31 |
mediated isothermal | 31 |
poisson regression | 31 |
cfu ml | 31 |
electron microscope | 31 |
murine leukemia | 31 |
pharmaceutical interventions | 31 |
environmental temperature | 31 |
average time | 31 |
proteomic analysis | 31 |
chronic diseases | 31 |
biological activity | 31 |
factor model | 31 |
chinese population | 31 |
group compared | 31 |
lung inflammation | 31 |
bars represent | 31 |
tertiary care | 31 |
renal failure | 31 |
primary infection | 31 |
transplant recipients | 31 |
disease risk | 31 |
molecular evolution | 31 |
economic burden | 31 |
backyard chickens | 31 |
invasive mechanical | 31 |
newly discovered | 31 |
one sample | 31 |
tetherin antagonism | 31 |
days later | 31 |
case patients | 31 |
death rate | 31 |
interferon alpha | 31 |
viruses including | 31 |
cell clones | 31 |
peptide inhibitors | 31 |
natural host | 31 |
across countries | 31 |
may vary | 31 |
higher mortality | 31 |
loop region | 31 |
nuclear localization | 31 |
media use | 31 |
fusion construct | 31 |
south america | 31 |
multicenter study | 31 |
stress response | 31 |
herd immunity | 31 |
among health | 31 |
membrane oxygenation | 31 |
maternal vaccination | 31 |
transmission electron | 31 |
longer time | 30 |
blood vessels | 30 |
untreated cells | 30 |
human irf | 30 |
inhibitor cocktail | 30 |
relative abundance | 30 |
hcv infected | 30 |
force field | 30 |
infected individual | 30 |
nucleotide identity | 30 |
sentinel sites | 30 |
developed countries | 30 |
two methods | 30 |
infection using | 30 |
pr virus | 30 |
surgical indications | 30 |
beckman coulter | 30 |
viruses detected | 30 |
respiratory secretions | 30 |
mixing patterns | 30 |
patients presenting | 30 |
control samples | 30 |
san jose | 30 |
animal experiments | 30 |
statistical methods | 30 |
papillomavirus type | 30 |
data presented | 30 |
natural infection | 30 |
first line | 30 |
saharan africa | 30 |
many cases | 30 |
san cristobal | 30 |
feature set | 30 |
clinical significance | 30 |
acid tests | 30 |
adjusted odds | 30 |
rt activity | 30 |
communicable disease | 30 |
using high | 30 |
expression profiling | 30 |
canine parvovirus | 30 |
collected swabs | 30 |
also analyzed | 30 |
inflammatory markers | 30 |
rhesus macaque | 30 |
th march | 30 |
brown bats | 30 |
dengue ns | 30 |
large scale | 30 |
st cells | 30 |
high specificity | 30 |
drug administration | 30 |
considered positive | 30 |
time quantitative | 30 |
final extension | 30 |
thermal stability | 30 |
larger number | 30 |
also associated | 30 |
normally distributed | 30 |
patients showed | 30 |
generation sequencing | 30 |
reported data | 30 |
corneal cells | 30 |
also provide | 30 |
monkey kidney | 30 |
pdm infection | 30 |
fruit bat | 30 |
younger age | 30 |
cycling conditions | 30 |
alveolar cells | 30 |
i interferons | 30 |
becton dickinson | 30 |
case reporting | 30 |
van der | 30 |
shock protein | 30 |
england biolabs | 30 |
vaccine effectiveness | 30 |
cellular localization | 30 |
aa diet | 30 |
sequenced using | 30 |
gene encoding | 30 |
modelling study | 30 |
coronavirus outbreak | 30 |
simple method | 30 |
large proportion | 30 |
systems biology | 30 |
bombyx mori | 30 |
terminal sequence | 30 |
among people | 30 |
wallis test | 30 |
pseudo amino | 30 |